Icosapent Ethyl

pharmacological · cardiovascular · immune-hematologic · Oral

Icosapent Ethyl. Ethyl ester of pure EPA (no DHA) — pharmaceutical grade ω-3. REDUCE-IT trial (2018) demonstrated 25% MACE reduction in… Oral half-life 3 d.

Ethyl ester of pure EPA (no DHA) — pharmaceutical grade ω-3. REDUCE-IT trial (2018) demonstrated 25% MACE reduction in statin-treated high-risk patients with elevated triglycerides. Mechanism beyond TG-lowering involves stabilization of atherosclerotic plaque + anti-inflammatory eicosanoid shift.